Tail-anchored (TA) proteins insert into their target organelles by incompletely elucidated posttranslational pathways. Some TA proteins spontaneously insert into protein-free liposomes, yet target a specific organelle in vivo. Two spontaneously inserting cytochrome b5 forms, b5-ER and b5-RR, which differ only in the charge of the C-terminal region, target the endoplasmic reticulum (ER) or the mitochondrial outer membrane (MOM), respectively. To bridge the gap between the cell-free and in cellula results, we analyzed targeting in digitonin-permeabilized adherent HeLa cells. In the absence of cytosol, the MOM was the destination of both b5 forms, whereas in cytosol the C-terminal negative charge of b5-ER determined targeting to the ER. Inhibition of the transmembrane recognition complex (TRC) pathway only partially reduced b5 targeting, while strongly affecting the classical TRC substrate synaptobrevin 2 (Syb2). To identify additional pathways, we tested a number of small inhibitors, and found that Eeyarestatin I (ES I ) reduced insertion of b5-ER and of another spontaneously inserting TA protein, while not affecting Syb2. The effect was independent from the known targets of ES I , Sec61 and p97/VCP. Our results demonstrate that the MOM is the preferred destination of spontaneously inserting TA proteins, regardless of their C-terminal charge, and reveal a novel, substratespecific ER-targeting pathway.
| INTRODUCTION
During the past decades, enormous progress has been made in deciphering the targeting/sorting signals carried by newly synthesized proteins and in characterizing the cellular machinery that decodes these signals, ensuring delivery of each protein to its cognate compartment. Nevertheless, and notwithstanding the current detailed structural and functional understanding of the major biogenetic pathways (reviewed in References 1-3), ongoing research in the field continues to unveil new players and phenomena, revealing unanticipated complexities of organelle biogenesis. For instance, while it was previously thought that single targeting pathways are uniquely responsible for the delivery of classes of proteins to the correct destination, it now appears that different pathways may handle the same protein cargoes, 4 thereby buffering the cell against the detrimental effects of protein mislocalization that could be caused by insufficiency of a single targeting mechanism.
An example of a class of proteins that use more than one targeting pathway to reach the same organelle is offered by tail-anchored (TA) proteins, many of which are involved in fundamental processes such as apoptosis, membrane trafficking and protein translocation.
TA proteins feature a C-terminal module, comprising the transmembrane domain (TMD) plus a few downstream polar residues, which confers the capacity to integrate into bilayers as well as the targeting specificity, and an N-terminal, cytosolic module, which carries out the protein's function. After release from the ribosome, most TA proteins posttranslationally target the endoplasmic reticulum (ER) or the mitochondrial outer membrane (MOM). While the ER appears to be able to accept TA proteins with different TMD length and hydrophobicity, a moderately hydrophobic TMD coupled to C-terminal positive charge is the feature that determines targeting to the MOM (reviewed in References 5 and 6). Delivery of TA proteins to the ER and to the MOM does not rely on the classical import machinery of these 2 organelles, the Sec61 translocon and the translocase of the outer membrane (TOM) machinery, respectively. [7] [8] [9] [10] [11] [12] [13] So far, membrane machinery involved in MOM TA protein integration has not been discovered, 13 and while some MOM TA proteins require cytosolic chaperones to prevent their aggregation before delivery to their destination, 14 others are capable of targeting the MOM in the absence of any cytosolic factor. 12 In the case of the ER, instead, an important targeting pathway, the guided entry of tail-anchored (GET)
proteins or transmembrane recognition complex (TRC) pathway, in yeast and mammals, respectively, was discovered 10 years ago, 10, 15, 16 and has since then been characterized in great detail (reviewed in .
The central player of the GET/TRC pathway, the cytosolic GET3/ TRC40 ATPase, receives the TMD of ER-directed TA proteins from a pre-targeting complex, and delivers it to the ER after interacting with a receptor on the ER membrane (Get1/2 in yeast 16, 21, 22 ; WRB/CAML in mammals [23] [24] [25] [26] ). In cell-free systems, many mammalian TA proteins are strongly dependent on the TRC pathway. 10, 15 Similarly, in S. cerevisiae, a number of overexpressed TA proteins mislocalize in GET-deficient strains. 16 Yet, recent studies on cultured cells 27 and on mice carrying tissue-specific deletions of TRC40 28 or WRB 29 have revealed that many TA proteins of the ER are expressed at normal levels and correctly localized in the TRC-deficient cells. Similarly, in GET-deficient yeast, most TA proteins, expressed at moderate levels, are correctly localized. 29 Thus, alternative pathways can compensate for loss of the GET/TRC machinery.
A particularly intriguing problem concerns the targeting mechanisms of those TA proteins that, in cell-free systems, are capable of nonassisted or spontaneous insertion into lipid bilayers, as is the case of cytochrome b 5 (b5). 9, 30, 31 In mammals, 2 different genes (CYB5A and B in human) code for 2 isoforms of b5, of which the more abundantly expressed one is specifically targeted to the ER, while the minor form is found only on the MOM. 32 Mutational analysis demonstrated that the targeting determinant is contained in the C-terminal tail region, 33, 34 which is negatively charged in the ER form, and positively charged in the MOM version. Replacement of the last 6 residues of the ER b5 form with an arginine completely reroutes the protein to the MOM, illustrating how the combination of C-terminal positive charge and moderately hydrophobic TMD the latter a feature of both b5 isoforms -determines targeting to mitochondria. In the current study, we refer to the native, ER-targeted form of b5 as b5-ER, and to the mutant, MOM-targeted, version as b5-RR.
Although the localization of b5-ER and b5-RR, when transfected into cultured cells, is remarkably specific, this precise targeting is not recapitulated in cell-free systems. As a matter of fact, in vitro translated b5-RR posttranslationally translocates its C-terminus into ER-derived microsomes as efficiently than b5-ER. 34 Furthermore, b5-ER can translocate its C-terminus across microsomes or protein-free liposomes in the absence of any cytosolic factor. 9, 31 The basis of the highly specific in vivo localization of the 2 b5 forms, in the face of their promiscuous behavior in cell-free systems has remained mysterious until now.
Here, to bridge the gap between the studies in cell-free systems and in vivo, we have used digitonin-permeabilized adherent cultured mammalian cells (semi-permeabilized [SP] cells) exposed to recombinant forms of the 2 proteins or to the in vitro synthesized products released from ribosomes. We find that, in the absence of cytosol, the MOM is the preferred destination for both b5 forms, but that cytosolic factors reroute b5-ER to the ER, while not affecting b5-RR targeting to the MOM. Furthermore, more than 1 mechanism is involved in the cytosol-dependent targeting to the ER, in agreement with the idea that redundant, but substrate-specific, targeting pathways compete with spontaneous insertion into the MOM to specifically deliver a subset of TA proteins to the ER.
| RESULTS

| Recombinant b5 forms are correctly targeted in microinjected cells
To explain the discrepancy between the precise in vivo targeting of b5-ER and b5-RR and their promiscuous behavior in cell-free systems, we considered the possibility that the capacity of the 2 forms to discriminate between the ER and the MOM might depend on a segregated localization of their mRNAs, as reported for Sec61β, 35 or on ribosome-associated factors, which would capture the substrate immediately after the release from the ribosome. 36, 37 If either of these mechanisms were operating, the purified recombinant proteins, microinjected into the cytosol of cultured cells, would be incapable of correct targeting. Instead, as illustrated in Figure 1 , 15 minutes after microinjection, we observed a remarkably specific localization of each of the 2 recombinant proteins: b5-ER showed a pattern similar to the ER marker protein disulfide isomerase (PDI), with prominent nuclear envelope staining, and no co-localization with a mitochondrial marker ( Figure 1A ), whereas b5-RR showed a high degree of localization to mitochondria revealed by TOM22 staining ( Figure 1B) . Thus, the specific targeting information of the 2 b5 forms is contained exclusively in the proteins themselves, and targeting can occur independently from ribosome-associated factors.
2.2 | In SP cells, both b5 forms target mitochondria in the absence of cytosol; b5-ER, but not b5-RR is rerouted to the ER in the presence of cytosol and energy
To investigate the basis of the observed in vivo targeting, we analyzed the localization of the 2 recombinant proteins in digitoninpermeabilized (SP) cells. After permeabilization, the cytosol was washed away, and each of the recombinant proteins was incubated with the cells in the presence of buffer alone or of an exogenous source of cytosol (rabbit reticulocyte lysate, RRL). As shown in Figure 2A , in the absence of cytosol, both b5-RR (left) and b5-ER (right)
showed a prominent co-localization with the MOM marker and did not appear to target the ER. Determination of Mander's coefficient in the images confirmed the mitochondrial localization of both forms, and, importantly, revealed that their distribution was indistinguishable ( Figure 2B ). In contrast, when RRL was present during the incubation, b5-ER was in large part, although not completely, shifted to the ER, as indicated by the clear nuclear envelope staining ( Figure 2A , right, middle column), whereas the distribution of b5-RR was unaltered ( Figure 2A , left, middle column). Quantification with Mander's coefficient confirmed the effect of cytosol in shifting the distribution of b5-ER from mitochondria to the ER and revealed that, under this condition, the distributions of the 2 b5 forms were significantly different ( Figure 2B ).
To assess whether the 2 b5 forms were stably integrated in the organelle bilayers under the 2 conditions, or whether they were only peripherally associated, we subjected cell homogenates to alkaline extraction, and separated the samples into an alkaline-resistant and alkaline-extracted fraction. We found that both b5 forms, after incubation either with buffer alone or with RRL, were tightly associated with the bilayers, as they were entirely recovered in the pellet fraction, together with the integral membrane protein calnexin (Cnx) and separated from the soluble, lumenal protein, PDI ( Figure 2D ).
FIGURE 1
Microinjected recombinant b5-ER and b5-RR are targeted to mitochondria and the ER, respectively. CV1 cells were microinjected with b5-ER (A) or b5-RR (B). The 2 constructs are schematically depicted in each panel: red oval and hashed blue rectangle represent the catalytic and transmembrane domain of the principal mammalian isoform of cyt b5, respectively. The sequence downstream to the TMD, which differs in b5-ER and b5-RR, is shown. Fifteen minutes after the microinjection, the cells were fixed and stained for b5 (red), PDI (ER marker, green) or TOM22 (MOM marker, green) as indicated. The asterisk in panel A indicates a cell that was not microinjected. The images shown are representative of ≥3 independent experiments, in which 50 to 100 cells were microinjected. Scale bars, 10 μm We also investigated a possible energy requirement for the cytosol-dependent localization of b5-ER. Under energy-depleted conditions, b5-RR remained associated with mitochondria ( Figure 2A , left, third column and Figure 2B ), whereas the ER localization of b5-ER was significantly decreased, and its localization to mitochondria slightly increased ( Figure 2A , right, third column and Figure 2B ). A major effect of energy depletion was a decreased b5 content of the SP cells ( Figure 2C ), indicating less membrane insertion and consequent extraction during the wash steps following the import reaction. This phenomenon was especially prominent for b5-ER. Thus, cytosolic factors, at least some of which are energy-dependent, are required to hinder b5-ER's integration into the MOM and to deliver it to the ER.
In order to monitor translocation across the ER membrane biochemically, we turned to a b5-ER construct that carries an opsin tag at its C-terminus; the tag bears an N-glycosylation consensus sequence, whose utilization reports on exposure of the C-terminus to the lumenally located oligosaccharyl transferase complex ( Figure 3A ). We first verified whether the construct (called b5-ops) showed the same targeting behavior as the untagged b5-ER in SP cells. As illustrated in Figure 3B , indeed, under the condition of buffer alone (top row), b5-ops showed prominent co-localization with the MOM marker, while it was shifted to a completely different pattern in the presence of RRL (bottom row), with the prominent nuclear envelope staining reporting on ER localization. A similar result was obtained with RRL, from which ribosomes had been eliminated by ultracentrifugation ( Figure S1 , Supporting information), confirming that ribosome-associated factors are not required for the targeting. In accordance with the immunofluorescence data, in the presence of RRL, a glycosylated form of b5-ops was generated, which was absent when the import assay was done in buffer alone ( Figure 3C ). Thus, the behavior of b5-ops in SP cells is similar to the one of the untagged protein, allowing us to use glycosylation as a means to monitor ER insertion.
To establish optimal conditions for the import assay, we carried out a time course of glycosylation of b5-ops, and found that the extent of glycosylation approached a plateau between 40 and 60 minutes, justifying a 1-h incubation for our assay ( Figure 3D ). As shown in Figure 4A , WRBcc, compared to a mutant WRBcc form (WRB R77E) that cannot interact with TRC40, 21, 38 caused a modest (~30%) but statistically significant reduction in glycosylation of recombinant b5-ops ( Figure 4A ). We then compared the effect of WRBcc on b5-ops and a construct, in which b5's moderately hydrophobic TMD is replaced with the more hydrophobic one of Synaptobrevin 2 (called Syb2-ops, Figure 4B ). We previously demonstrated that this construct requires a functional TRC system for integration into microsomes. 26 For this comparison, we supplied the in vitro translated products, released from ribosomes via the natural stop codons, to the SP cells, because recombinant Syb2-ops is insoluble. As can be seen in Figure 4B , glycosylation of Syb2-ops was nearly completely inhibited by WRBcc, which, again, had a mild effect on b5-ops.
A similar result was obtained when 2 different siRNAs were used to deplete WRB from the cells. Glycosylation of both the recombinant protein and in vitro translated b5-ops were mildly inhibited by WRB depletion, and again, Syb2-ops was more strongly affected ( Figure 4C,D) . Finally, depletion of TRC40 from the RRL also produced a statistically significant 30% to 40% inhibition of recombinant b5-ops glycosylation ( Figure 4E ), differently from the previously observed lack of effect in cell-free systems. To confirm that the partial effects of TRC40 depletion and WRB inhibition were not caused by incomplete removal of TRC40 and/or insufficient activity of WRBcc, we investigated the effect of the simultaneous interference with both these components ( Figure 4F ).
Again, both WRBcc and TRC40 depletion singly caused a modest inhibition of b5-ops glycosylation (32% and 39% inhibition, respectively). Importantly, when TRC40-depleted RRL was supplemented with WRBcc, no additional inhibition of b5-ops targeting was observed over that found by TRC40 depletion alone, confirming that the 2 treatments were acting on the same pathway, and suggesting that complete inhibition of the pathway allows 60% or more of b5-ops to be faithfully targeted to the ER. In summary, with 3 different approaches, we found that the TRC pathway plays a role in b5 targeting; however, since the inhibition is mild, additional pathways must be operating.
Recently, a new targeting system has been described in yeast, the SRP-Independent (Snd) pathway, which handles membrane proteins carrying TMDs removed from the N-terminus, and complements the activity of the SRP and Get pathways. 4 Two of the Snd proteins, Snd2 and 3, are ER proteins, and are thought to act as receptors in the targeting process. Since Snd2 has a mammalian homolog, TMEM208 (referred to as hSnd2 39 ), we investigated its effect on b5-ops targeting by silencing it with 4 different oligonucleotide pairs. Although we obtained efficient depletion with all 4 siRNAs, inhibition of b5-ops glycosylation was absent (siRNAs #1
and 2) or at most very weak (siRNAs #3 and 4, Figure 5A ). We reasoned that the TRC pathway might be compensating for hSnd2 loss, as recently observed in a co-translational cell-free system, 39 so we assayed for b5-ops glycosylation in SP cells silenced for both WRB and hSnd2. Also in WRB-silenced cells, however, the effect of hSnd2 deletion was very weak (~10% inhibition), suggesting that the Snd pathway is at most marginally involved in the posttranslational targeting of b5, and motivating us to seek alternative targeting pathways. ES I is a bifunctional compound, with an aromatic, membranebinding domain, and a nitrofuran-containing group, responsible for its biological activity. 43 To investigate whether ES I 's interference with b5 targeting was attributable simply to a physico-chemical effect of the aromatic domain on the ER bilayer, we tested the effect of a related compound ES R35 , which contains only the membraneinserting domain. 42, 43 As shown in Figure 6C , at 20 μM concentration, a condition in which ES I caused a 33% reduction in b5-ops glycosylation, ES R35 was ineffective, and even at 100 μM it had a very weak effect compared to the parent compound. Thus, the nitrofuran-containing domain is required for the inhibitory effect of ES I on b5-ops glycosylation.
| An Eeyarestatin 1 (ES I
Our next question was whether ES I would similarly affect a bona fide TRC40 substrate. Thus, we compared the effect of the inhibitor (Figure 6D ), even at high concentration of the compound (graph in Figure 6D ). Importantly, this result demonstrated that ES I is not affecting the glycosylation machinery, and thus, that it targets b5-ops' delivery to-or translocation across the ER membrane.
Given the lack of effect of ES I on Syb2-ops, we considered that the effect on b5-ops might be due to a particular, and specific, interaction between b5 and the inhibitor. To test this possibility, we assessed the effect of ES I on the glycosylation of another opsin-tagged protein, PTP1B. This protein has a completely unrelated sequence to b5, but, like b5, has a moderately hydrophobic TMD, and can insert spontaneously into protein-free liposomes. 30 Because only a small portion of PTP1B was glycosylated in the import assay, and because the glycosylated and unmodified forms are poorly resolved in SDS-PAGE, in this experiment we separated the glycosylated products from the unglycosylated ones by Concanavalin A-Sepharose affinity capture. Again, ES I did not interfere with Sy2-ops glycosylation, but had a similar effect on b5-ops and PTP1B-ops ( Figure 6E ).
Finally, we asked whether ES I would interfere with MOM targeting of TA proteins, which generally feature a moderately hydrophobic TMD. To this end, we investigated its effect on the targeting of b5-RR.
As shown in Figure 6F , this b5 form targeted the MOM equally in ES I or vector-treated cells. Thus, ES I appears to specifically target a pathway for delivery to the ER of spontaneously inserting TA proteins.
The most well characterized target of ES I is the AAA ATPase p97/valosin-containing protein (here referred to as p97). 41, 43 We found that the p97 ATPase inhibitors DBeQ and NMS-873 were without effect on b5-ops glycosylation, suggesting that p97 is not involved in the pathway (unpublished results). Nevertheless, to definitely rule out a role of this ATPase, we carried out the import assay under conditions of p97 depletion. The soluble pool of p97 was depleted by affinity capture of the p97 contained in the RRL, using a fusion between GST and the p97 binding fragment (UT6) of Ufd1 as bait 44 ( Figure 7A , top), while the membrane associated pool was depleted from the cells by silencing ( Figure 7A , bottom). Depletion of p97 from the RRL, the cells, or from both, had no effect on b5-ops glycosylation ( Figure ES I has also been reported to interfere with the function of the Sec61 translocon. 42, 45 Under our conditions, we did not detect an effect of ES I on the processing of the SRP substrate pre-prolactin ( Figure 7C ). Again, to definitely rule out a role of Sec61 in the ES Isensitive pathway, we carried out the import assay with SP cells silenced for Sec61. As illustrated in Figure 7D , a nearly 90% depletion of Sec61 had no effect on b5-ops glycosylation, and ES I was equally effective as inhibitor in control or silenced cells. Thus, neither p97
nor Sec61 appear to be involved in the ES I -sensitive pathway.
| Additive effect of the ES I -sensitive and the TRC pathway
The results obtained so far indicated that 2 different pathways, the hydrophobic TMDs, 5 and, thanks to this feature, are able to spontaneously insert into protein-free bilayers. 11, 46 The ER is instead capable of accepting TAs with higher hydrophobicity (eg, SNARE proteins destined to downstream compartments of the secretory pathway); however, a number of its resident TA proteins have TMDs with 
| In vivo targeting occurs independently from mRNA localization or ribosome-associated factors
To account for the discrepancy between in vivo and in vitro targeting of the 2 b5 forms, we considered a number of mechanisms that might operate in cells but not in cell-free systems. One mechanism that is thought to contribute to TA protein targeting is the capture of newly synthesized substrates by ribosome-associated targeting factors that would prevent their aggregation after release from the ribosome. 36, 37 Another potential mechanism could be contributed by mRNA localization. 47 In the case of TA proteins, Cui et al 35 reported that the mRNAs coding for Sec61β and for nesprin are partially localized to the ER, thus facilitating the subsequent insertion of the translated Figure 4E . The graph below the blot shows the average glycosylation, normalized to control values, of 2 independent experiments. (B) The inhibition of b5-ops glycosylation by combined TRC40 depletion and ES I is close to the value expected for additive effects of each single treatment polypeptides. Finally, the precision of TA protein localization can be fine-tuned by postinsertional quality control mechanisms, as exemplified by the AAA ATPase Msp1/ATAD, 48, 49 which extracts mislocalized TA proteins from the MOM for subsequent degradation. 50 The remarkable precision with which the recombinant forms of the 2 b5 proteins targeted their cognate organelle after microinjection into the cytosol of cultured cells demonstrates that neither ribosome-associated factors nor mRNA localization is required for them to discriminate between the ER and the MOM. Furthermore, it is highly unlikely that postinsertional quality control mechanisms were operating in the mere 15 minutes that followed microinjection, since Msp1, at least, operates on a time-scale of hours. 48, 49 Thus, our results demonstrate that the 2 released b5 forms carry targeting information that the cells can interpret, even when acutely faced with an unusual load of the recombinant proteins.
| In the absence of cytosol, the MOM is the preferred destination for both b5 forms
Investigations in yeast demonstrated that a number of ER TA proteins mislocalize to the mitochondria in the absence of a functional Get pathway, 16 suggesting that the MOM may represent the default destination for TA proteins (provided that they have a compatible moderately hydrophobic TMD), and that the Get system prevents them from targeting the MOM while delivering them to the ER. In metazoans, however, the rerouting of an ER TA protein to mitochondria, as observed by us in SP cells under cytosol-free conditions, had not been reported. This result demonstrates unequivocally that, in the absence of cytosolic factors, the MOM is the preferred destination for both b5-ER and b5-RR. Thus, the C-terminal negatively charged polar region of b5-ER in itself does not interfere with insertion into the MOM; rather, it must act by recruiting kinetically favored targeting factors that hinder its association with mitochondria and direct it to the ER.
We presently do not know how the positive charges at the Cterminus of MOM TA proteins exclude them from ER-targeting pathway(s). A recent detailed analysis in yeast 51 has revealed that TA binding to the first chaperone of the Get pathway, Sgt2, as well as handover from Sgt2 to Get3 is influenced mainly by TMD hydrophobicity and α-helicity, and not by the charge of the segment downstream to the TMD. The latter feature, instead, determines a reduction in the kinetics of release of the TA substrate from Get3 to the ER bilayer. While it is possible that this mechanism operates also in mammals, we note that in a cell-free system, the extent of glycosylation of opsin-tagged b5-RR by ER microsomes was comparable to that of the corresponding b5-ER construct, suggesting that the positive charges were not hindering translocation across the ER bilayer. 34 Rather than a reduced rate of insertion into the ER, we therefore favor the idea that a positively charged C-terminal region enhances the rate of integration into the MOM, which would therefore win over the multiple competing, but slower, ER targeting factors. Unfortunately, so far, we have been unable to directly measure the kinetics of the association of the 2 b5 forms with the MOM, because of the absence of a posttranslational modification that could be used to monitor the translocation of their C-terminus.
An important and unresolved question is the nature of the features of the MOM that underlie its function as default destination of TA proteins with compatible TMDs. Mitochondrial import machinery involved in the integration of TA proteins into the MOM or dedicated targeting factors have so far not been discovered either in yeast 13 or in mammals. 12 Since sterols inhibit the insertion into bilayers of unassisted TA proteins, 9,11 and since, in yeast, an alteration in the balance between sterol levels of the ER and the MOM causes partial mistargeting of a MOM TA protein to the ER, it has been suggested that the particularly low sterol levels of the MOM facilitate unassisted insertion. 13 While this might be the case in yeast, we note that the scant literature on the lipid composition of the MOM and ER membrane in mammals 52,53 reported a similar sterol content of these 2 membranes. Thus, the mammalian MOM's cholesterol content, while low compared to compartments of the late secretory pathway, may not be the feature that distinguishes it from the ER.
Mitochondria, like their bacterial ancestors, contain the phospholipid cardiolipin, which is mainly present mainly in the inner membrane, where it is synthesized, but it also is transported from the inner to the outer membrane (reviewed in Reference 54). Within the MOM, cardiolipin's distribution is not homogeneous: thus, although its overall MOM concentration is low, it may constitute over 20% of the lipids at contact sites between the inner and the outer membrane. 53 Cardiolipin is a cone-shaped phospholipid that carries unsaturated fatty acyl chains, thus destabilizing phospholipid bilayers.
Disordered bilayer domains at inner membrane-MOM contact sites could represent hotspots for the insertion of TA proteins. In agreement with this idea, a role for cardiolipin has been demonstrated in the recruitment of soluble proteins to the mitochondrial surface, 55, 56 and, in yeast, it has been implicated in the biogenesis of outer membrane multispan proteins. 57 3.3 | TRC pathway and a novel ES I -sensitive mechanism are involved in the ER targeting of unassisted TA proteins
Our search for the mechanisms that hinder association of b5-ER with the MOM and deliver it to its correct destination revealed that 2 pathways, the well-characterized TRC pathway and a previously unknown ES I -sensitive pathway, together account for~65% of the delivery of b5-ops to the ER.
The involvement of the TRC pathway was not unexpected, as a TMD-dependent association of b5 with TRC40 had been previously observed, 31, 58 although its functional significance was not understood. The partial requirement of b5 targeting for the TRC pathway in SP cells contrasted with the near complete dependence of a bona fide TRC40 substrate, indicating that additional pathways were operating for b5 targeting. Among these, we identified one that is sensitive to the ERAD inhibitor ES I .
Very interestingly, the effect of ES I was remarkably selective for TA proteins with moderately hydrophobic TMDs, as Syb2-ops glycosylation was totally insensitive to the compound even at high concentration. ES I 's inhibitory effect did not depend on any particular sequence feature of the substrate, as it was effective also on a TA protein with a completely unrelated sequence, and was inactive on the b5-RR construct that targets the MOM, indicating that it was affecting a targeting factor and not the substrates themselves. Furthermore, the nitrofuran moiety, which carries its biological activity, 43 was required for its activity.
ES I has been best characterized as an inhibitor of ERAD, through its interaction with p97, an AAA ATPase that extracts misfolded substrates from the membrane or lumen of the ER for their subsequent proteasomal degradation. 41, 59 Additionally, it has been reported that ES I inhibits the Sec61 translocon, 42, 45 that it reduces the rate of protein synthesis and interferes with vesicular transport, 60 and that it induces the formation of adducts of members of the PDI family in the ER lumen. 61 Whether some of these effects are an indirect consequence of ES I 's action on its primary targets or whether additional components are targeted by the drug, is presently not known. Our finding that neither p97 nor Sec61 are involved in the TA protein targeting pathway uncovered here, suggests a novel ES I target that remains to be identified.
| CONCLUSIONS
Our results give strong support to the hypothesis of the MOM as default destination for all TA proteins capable of unassisted insertion, independently of the charge of the extreme C-terminal polar region.
Positive charges in this location would allow substrates to avoid competing, chaperone-mediated, pathways that underlie ER targeting.
Among these, the TRC pathway is well-characterized, but additional ones that ensure delivery of TA proteins to the ER deserve further investigation.
| MATERIALS AND METHODS
| Reagents
High purity digitonin, from Calbiochem (Merck S Elmer Life Sciences. All other reagents were from Sigma-Aldrich.
| Plasmids
The plasmids containing the sequence of the principal, ER-localized, isoform of rabbit cytochrome b5 under the CMV promoter, and a variant thereof, in which the last 6 codons of the above sequence are substituted with a codon specifying an Arg residue, were described in Reference 34. We refer to the proteins encoded in these plasmids as b5-ER and b5-RR (schematized in Figure 1 ). These 2 plasmids were used in the microinjection experiment of Figure 1 .
The b5-ops, PTP1B-ops and b5-Syb2-ops constructs in pGEM4, used for in vitro translation, are described in Reference 30, where they are referred to as b5-ops-28, PTP1B-ops-35 and b5-Syb2-ops28, respectively. All 3 constructs contain a C-terminal opsin epitope. In b5-Syb2-ops, the TMD of b5 is replaced with the one of Syb2; for brevity, we refer to this construct as Syb2-ops (schematized in Figure 4B ). The PTP-1B construct contains the entire PTP1B
sequence, including the cytosolic domain and the TMD, followed by the opsin epitope.
The pGEX2T-b5ER and the pGEX2T-b5-ops plasmids are described in References 62 and 31, where they are referred to as b5-wt and pGEX-GST-b5-ops28, respectively. pGEX2T-b5RR was obtained from 
| Antibodies
The primary antibodies used in this study are listed in Table S1 . 
| Recombinant proteins
b5-ER, b5-RR and b5-ops were prepared from detergent lysates of induced Escherichia coli BL21 as previously described. 31 After capture by glutathione beads, detergent was removed and the recombinant proteins were released by thrombin diluted in PBS.
WRBcc and WRBcc R77E (Mut WRBcc), encoded in pQE plasmids, were prepared from the soluble fraction of a sonicate of induced BL21 cells as previously described, 26 with the difference that digestion with GST-tobacco etch virus protease was done on the preparation released from the amylose affinity resin by maltose. The resulting preparations, containing MBP plus the cleaved WRBcc forms, were used in import assays.
GST-UT6, expressed in E. coli BL21 and released from the bacteria by sonication, was captured on glutathione-Sepharose 4B beads and used for p97/VCP depletion from the RRL. Seven milliliter of sonicate, containing~2.5 mg of fusion protein were immobilized on 0.5 mL of packed beads. GST alone, expressed from pGEX2T, was similarly immobilized, as control. The purity of all the recombinant proteins was checked by SDS-PAGE ( Figure S2 ). CV1 cells were used for microinjection of recombinant proteins as previously described, 31 whereas import assays were carried out with SP HeLa cells (as described below).
| RRL mix
HeLa cells were transfected using the jetPei (Polyplus) transfection reagent according to the instructions of the manufacturer.
siRNA transfection was carried out with the RNAiMAX Lipofectamine reagent (Thermo Fisher), following the manufacturer's protocol. The targets of silencing, the siRNA sequences and sources, and the conditions of silencing are reported in Table S2 . 
| Treatments of RRL
Energy depletion: for import assays under energy depleted conditions, ATP, GTP, phosphocreatine and creatine kinase were omitted from the RRL mix, and any residual ATP was depleted from the samples by a hexokinase/glucose trap (30 mM glucose and 2.5 μg/mL hexokinase).
TRC40 depletion: TRC40 was depleted from the RRL by immobilized anti-TRC40 antibody, as previously described. 31 Mock-depleted RRL was produced by incubation with equal amounts of immobilized Detection of radioactive translation products was done with the Storm phosphoimager (GE-Healthcare). Band intensities were quantified with Image Quant TL 7.0 software.
| Immunofluorescence and image analysis
PFA-fixed cells were processed for immunofluorescence by standard procedures, using Triton-X-100 as permeabilization agent. To detect cytosolically exposed epitopes in SP cells, detergents were omitted. 
| Statistical analysis
Comparisons between 2 groups were carried out by paired Student's t test. Multiple comparisons among groups were carried out by oneway ANOVA and Bonferroni's post-test (Prism software). In the figures, the following symbols are used: ns (nonsignificant), P ≥ .05; *, P < .05; **, P < .01.
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